Health Care & Life Sciences » Pharmaceuticals | Concordia International Corp.

Concordia International Corp. | Balance Sheet

Fiscal year is January-December. All values CAD Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
46
50
216
534
410
Total Accounts Receivable
24
35
277
278
184
Inventories
4
8
140
124
96
Other Current Assets
3
6
37
21
21
Total Current Assets
77
98
670
958
711
Net Property, Plant & Equipment
-
1
7
7
4
Total Investments and Advances
-
-
-
32
-
Intangible Assets
104
587
6,649
4,007
2,191
Other Assets
-
-
9
-
-
Total Assets
181
686
7,338
5,004
2,910
ST Debt & Current Portion LT Debt
16
36
26
103
4,621
Accounts Payable
23
8
54
47
33
Income Tax Payable
1
-
58
61
63
Other Current Liabilities
41
51
570
356
408
Total Current Liabilities
81
95
708
567
5,126
Long-Term Debt
5
293
4,588
4,652
-
Provision for Risks & Charges
-
-
55
10
8
Deferred Taxes
7
1
378
242
166
Other Liabilities
-
-
23
1
38
Total Liabilities
116
388
5,731
5,511
5,304
Common Equity (Total)
65
298
1,606
506
2,394
Total Shareholders' Equity
65
298
1,606
506
2,394
Total Equity
65
298
1,606
506
2,394
Liabilities & Shareholders' Equity
181
686
7,338
5,004
2,910

About Concordia International

View Profile
Address
277 Lakeshore Road East
Oakville Ontario L6H 1J9
Canada
Employees -
Website http://www.concordiarx.com
Updated 09/14/2018
Concordia International Corp. is a pharmaceutical company, which engages in owning and licensing a diversified portfolio of branded and generic prescription products. It operates through the Concordia North America and Concordia International segments. The Concordia North America segment focuses primarily on the United States pharmaceutical market and offers products under the brand of Donnatal, Zonegran, Nilandron, Lanoxin, Plaquenil, and Photofrin.